logo
Here's one fella who can't wait to get his hands on the iPhone Air

Here's one fella who can't wait to get his hands on the iPhone Air

Digital Trends19-05-2025

The so-called 'iPhone Air' is apparently on the way, despite Apple remaining characteristically tight-lipped about such a device.
Numerous leaks have suggested that the iPhone Air, which is expected to launch this fall along with the iPhone 17, will be just 5.5mm thick, making it easily Apple's slimmest handset yet.
Recommended Videos
With that in mind, many are curious to see how well the device stands up to the highly unscientific bend test meted out by tech YouTuber Zack Nelson of the popular JerryRigEverything channel.
Whenever a high-profile handset hits the market, it's not long before Nelson puts it through a wince-inducing stress test that includes scratching, scraping, burning, and, right at the end, bending.
Over the years, at least five smartphones have succumbed to Nelson's notorious bend test, which involves nothing more than bending the device with his bare hands. Several handsets, like the One Plus 10 Pro, have snapped clean in two. And yes, it's always an excruciating watch.
In 2023, Nelson managed to shatter the glass back of the iPhone 15 Pro Max. 'You've been watching me durability test smartphones for about 11 years now, and most phones do not break,' Nelson said at the time. 'iPhones especially do not break … like, ever.'
While most folks are unlikely to ever apply the same amount of pressure to their handset — even accidentally — you can bet that Apple has been working hard on ways to ensure that the Air avoids a repeat of the so-called 'bendgate' scandal that hit the iPhone 6 and larger iPhone 6 Plus in 2014.
The issue was linked to the phone's larger size and thinner aluminum frame, with weak points near the volume buttons and antenna lines causing the phone to bend, especially when carried around in a tight pocket.
The tech giant will be doing what it can to ensure the iPhone 17 Air retains its structural integrity despite its ultra-thin design, though we'll have to wait until the phone's launch to fully understand how Apple has designed it to meet the challenge.
Even then, it kind of feels like a dead cert that the iPhone Air will fail Nelson's rather harsh test, with the likelihood being that the device will crack and crunch, and possibly even splinter and shatter, before disintegrating in his hands. Then again, perhaps we'll be pleasantly surprised …

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors
Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors

Yahoo

time20 minutes ago

  • Yahoo

Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors

Workiva Inc. (NYSE:WK) is one of the 11 Best Tech Stocks to Buy On the Dip. On May 29, Workiva Inc. (NYSE:WK) announced the appointment of Astha Malik, Chief Business Officer of Braze, to its board of directors. Malik brings 25 years of experience in driving growth and scaling high-growth SaaS companies. The company also released its Q1 2025 results on May 1. The revenue of $206 million grew 17% year-over-year driven by a 20% increase in subscription and support revenue. Both of these financial indicators surpass management's guidance despite a challenging environment characterized by a cautious buying environment and flat professional services revenue. A software engineer debugging a compliance code on a laptop in a modern office setting. After the earnings release, analyst Alexander Sklar from Raymond James maintained an Overweight rating on Workiva Inc. (NYSE:WK) lowering the price target from $125 to $105. The analyst noted the company showed strong bookings in Q1 however, the tough macroeconomic environment led to a conservative outlook by Raymond James. Regardless, Workiva Inc. (NYSE:WK) maintained its full-year revenue guidance at $864 million to $868 million. Workiva Inc. (NYSE:WK) is a technology company that operates a cloud-based platform that enables organizations to streamline and automate financial, sustainability, and compliance reporting processes. Its SaaS platform combines ERP, HCM, and CRM applications, supporting real-time collaboration and integrated reporting across teams. While we acknowledge the potential of WK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Melden Sie sich an, um Ihr Portfolio aufzurufen.

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Yahoo

time20 minutes ago

  • Yahoo

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Analysts reboot Micron Technology stock price target ahead of earnings
Analysts reboot Micron Technology stock price target ahead of earnings

Yahoo

time20 minutes ago

  • Yahoo

Analysts reboot Micron Technology stock price target ahead of earnings

Analysts reboot Micron Technology stock price target ahead of earnings originally appeared on TheStreet. An elephant might never forget but Micron Technology () has more storage space. The Boise, Idaho, company makes memory and storage chips for data centers, computers and smartphones, and its client list includes such tech-sector superstars as AI-chip chieftain Nvidia () , Mac and iPhone maker Apple () , Facebook parent Meta Platforms () and software kingpin Microsoft () . 💵💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰 Make no mistake, there's money in memories, and we're not just talking about those singing cats on Broadway. "After the historic downturn of 2022–2023, the memory industry has entered a phase of strong recovery. In 2024, memory revenue reached a record $170 billion,' according to market researcher Yole Group. "This rebound was fueled by AI-training requirements in data centers, with [high-bandwidth memory) playing a pivotal role due to its premium pricing and performance advantages," the firm added. HBM continues to outperform the broader DRAM chip segment, Yole Group said. This year HBM revenue is set to nearly double to around $34 billion. Micron is a key player in the HBM market, offering solutions like HBM3E and HBM4 designed for high-performance computing and AI applications. The company recently joined the Trump administration to unveil plans to expand its U.S. investments to about $150 billion in domestic memory manufacturing and $50 billion in research and development, creating an estimated 90,000 direct and indirect jobs. More Tech Stocks: Amazon tries to make AI great again (or maybe for the first time) Veteran portfolio manager raises eyebrows with latest Meta Platforms move Google plans major AI shift after Meta's surprising $14 billion move 'Micron's U.S. memory manufacturing and R&D plans underscore our commitment to driving innovation and strengthening the domestic semiconductor industry,' Chairman, President and CEO Sanjay Mehrotra said in a statement. The company's shares are up nearly up nearly 45% this year and off 16% from this time in 2024. Investment firms have been issuing research reports for Micron Technology ahead of its fiscal-third-quarter earnings report, scheduled for June 25. Wedbush boosted its price target on Micron to $150 from $130 while maintaining an outperform rating. The firm said memory-pricing trends turned more positive in the second quarter. And while Wedbush said it doesn't see as significant an inflection in Q3 as it had been expecting back in March, the firm said pricing for both DRAM and NAND, which are two types of semiconductor memory, "still will lift over the next couple of quarters." Better fundamentals are driven by stronger enterprise/server demand, which started around April and looks to hold through the rest of the year, Wedbush said. Demand for both AI and standard workloads appears better than might have been initially anticipated, it said. "Moreover, we view growing [high-bandwidth memory] requirements as not just positive for MU's numbers but also ultimately positive for industry dynamics as [capital spending] and clean-room space are reallocated to support HBM growth," Wedbush will limit the likelihood of too much supply of NAND/DRAM, and it increases the probability that production of more standard parts will trail demand. That, the firm said, would create a more positive pricing/margin cycle vs. what is embedded in its expectations, the firm said. Morgan Stanley maintained an equal-weight rating and $98 price target on Micron, given how much the stock has rallied already, according to The Fly. But the investment firm is "tactically bullish," given that AI spending is materially accelerating as Micron grows its participation. The investment firm, which notes that its estimates remain 20% above consensus for August-quarter earnings, also highlights Sandisk, () which it likes better long term and on which it has an overweight rating. Based in Milpitas, Calif., Sandisk designs and produces flash-memory products, including memory cards, USB flash drives and solid-state drives. Consensus numbers have started to come up for Micron over the past few weeks, but in addition to Morgan Stanley being about 20% above consensus for August earnings per share, the firm is also 14% above for November after it raised estimates six weeks reboot Micron Technology stock price target ahead of earnings first appeared on TheStreet on Jun 20, 2025 This story was originally reported by TheStreet on Jun 20, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store